Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $28.13 in the prior trading day, Harmony Biosciences Holdings Inc (NASDAQ: HRMY) closed at $29.07, up 3.34%. In other words, the price has increased by $3.34 from its previous closing price. On the day, 1.15 million shares were traded. HRMY stock price reached its highest trading level at $29.1775 during the session, while it also had its lowest trading level at $26.47.
Ratios:
Our goal is to gain a better understanding of HRMY by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.57 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.63. For the most recent quarter (mrq), Quick Ratio is recorded 3.27 and its Current Ratio is at 3.31. In the meantime, Its Debt-to-Equity ratio is 0.35 whereas as Long-Term Debt/Eq ratio is at 0.25.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on February 11, 2025, initiated with a Buy rating and assigned the stock a target price of $55.
On December 17, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $75.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 01 ’25 when Kapadia Sandip sold 6,987 shares for $32.54 per share. The transaction valued at 227,386 led to the insider holds 0 shares of the business.
SANDIP KAPADIA bought 6,986 shares of HRMY for $231,865 on Apr 01 ’25. On Mar 03 ’25, another insider, Dierks Jeffrey, who serves as the CHIEF COMMERCIAL OFFICER of the company, sold 4,869 shares for $32.67 each. As a result, the insider received 159,090 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HRMY now has a Market Capitalization of 1668231296 and an Enterprise Value of 1392152576. As of this moment, Harmony’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.58, and their Forward P/E ratio for the next fiscal year is 7.18. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.42. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.33 while its Price-to-Book (P/B) ratio in mrq is 2.52. Its current Enterprise Value per Revenue stands at 1.948 whereas that against EBITDA is 6.477.
Stock Price History:
The Beta on a monthly basis for HRMY is 0.86, which has changed by -0.07005757 over the last 52 weeks, in comparison to a change of 0.049593568 over the same period for the S&P500. Over the past 52 weeks, HRMY has reached a high of $41.61, while it has fallen to a 52-week low of $27.33. The 50-Day Moving Average of the stock is -16.21%, while the 200-Day Moving Average is calculated to be -16.48%.
Shares Statistics:
The stock has traded on average 687.56K shares per day over the past 3-months and 726740 shares per day over the last 10 days, according to various share statistics. A total of 57.14M shares are outstanding, with a floating share count of 43.54M. Insiders hold about 24.13% of the company’s shares, while institutions hold 83.12% stake in the company. Shares short for HRMY as of 1741910400 were 4114521 with a Short Ratio of 5.98, compared to 1739491200 on 3748832. Therefore, it implies a Short% of Shares Outstanding of 4114521 and a Short% of Float of 31.069999999999997.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
